Background {#Sec1}
==========

Colon cancer (CRC) has always be viewed as two different subtype since *Bufill* et al. firstly observed the clinical characteristics difference between right-sided colon cancer (RCC) and left-sided colon cancer (LCC) \[[@CR1]\].Since then, not only the classical characteristics differences such as RCC tend to have more proportion of anemia, intestinal perforation, mucinous histology type, higher CEA (carcino-embryonic antigen) level, younger female, etc. were proven in numerous studies, but also, the molecular features were found to be different between the two subtypes, for example, CpG island methylation, d-MMR(mismatch repair deficiency), KRAS mutation, EGFR A13 loss, BRAF mutation, etc. was more commoner in RCC \[[@CR2], [@CR3]\]. Recently, the difference of the two subtypes attract more interest because of their different reaction to targeted agents. *Gibbs* et al. has reported that in the patients received the Bevacizumab, the RCC patients has the most obvious PFS (progression-free survival) benefit \[[@CR4]\]. However, the results of the *Boisen* revealed that there exists the apparent survival advantage in the LCC when combined the chemotherapy with the Bevacizumab \[[@CR5]\]. Furthermore, in the metastasis-CRC in China and KRAS-wide patients, the combined cetuximab and chemotherapy could enhance the ORR (objective response rate), PFS (Progression-free survival) and OS (overall survival) in LCC patients without the survival benefit in the RCC \[[@CR6], [@CR7]\].

In the exploratory classification system of consensus molecular subtypes (CMS), CRC can be divided into four types \[[@CR8]--[@CR10]\]: CMS1 (MSI Immune, 14%), CMS2 (Canonical, 37%), CMS3 (Metabolic, 13%), and CMS4 (Mesenchymal, 23%), RCC and LCC also show different features. RCC relate to CMS2, with the features of SCNA high, microsatellite stable, weak immune activation, which might more insensitive to immunotherapy \[[@CR11]\]. The phase II clinical trial has demonstrated that only the mismatch repair--deficient (d-MMR) subset of CRC to be a good candidate for the PD-1 blockage immunotherapy \[[@CR12]\]. An estimated 20--25% of RCC stage II cancers being MSI-high (microsatellite instability-high) compared with the rare existence in LCC across all stages \[[@CR8]--[@CR10], [@CR13]--[@CR15]\], this partially explains the lower immunogenicity in LCC. In fact, the exact mechanism why lower immunogenicity in LCC which relate to CMS2 and its better outcome with the targeted therapy remained unknown \[[@CR4], [@CR7], [@CR11], [@CR16]\]. Recently, *Asaf* et al. has found that Ly6G + neutrophils suppress intraluminal natural killer cell (NK)-mediated tumor cell clearance and facilitate extravasation of carcinoma cells \[[@CR17]\], it indicate that inflammatory response may inhibit immune response. Does this correlation can help to explain the above mechanism? But the data of the difference of inflammatory parameters between RCC and LCC is rare. Though, some systematic inflammatory biomarkers such as the prognostic Nutritional Index (PNI), Glasgow prognostic score (mGPS), neutrophil lymphocyte ratio (NLR), and platelet lymphocyte ratio (PLR), have been shown to have prognostic value in various tumors, including CRC \[[@CR18]--[@CR20]\]. The prognostic value for CRC had been shown in the CRC, but not the Asians and it had not point out the prognostic difference in the LCC and RCC \[[@CR21]\].

Method {#Sec2}
======

A total of 1846 eligible colorectal cancer patients treated at Sun Yat-sen University Cancer Center between December 2003 and August 2015 were retrospectively enrolled after the exclusion criteria of patients without complete follow-up data. The inclusion criteria for the study are as follows: (i) pathological evidence of adenocarcinoma of CRC; (ii) complete baseline clinical information and laboratory data; and (iii) complete follow-up data. Treatment regimen is implemented based on the NCCN guidelines <https://www.nccn.org/>. Simply, stage I colon cancer receive radical surgery and colon cancer patients with low-risk stage II disease can be enrolled in a clinical trial, observed without adjuvant therapy, or considered for capecitabine or 5-FU/leucovorin(LV). For patients with high-risk stage II disease, they can be considered for adjuvant chemotherapy with 5-FU/LV (5-Fluorouracil/Leucovorin), capecitabine, FOLFOX (5- Fluorouracil+oxaliplatin+Leucovorin), CapeOX (Oxaliplatin+ Capecitabine), FLOX, or observation. Radiotherapy, chemotherapy and surgery were combined for the treatment of the stage III and stage IV colon cancer. In the present study, intensity-modulated radiation therapy (IMRT) was performed with 6--8 MV X-ray. The adjuvant chemotherapy was either one of FOLFOX, XELOX or Capecitabine alone with median cycles of 2 (range from 2 to 6 cycles \[[@CR22]\].

Patients with rectal cancer, as well as patients with the ascertained MSI status were excluded. The whole cohort was divided into two cohorts, with 923 patients in the training cohort from the January of 2004 to the November of 2013 and the other 923 patients in the validation cohort from December 2013 to the August 2015. Ethical approval was obtained from the institutions through the respective institutional review boards. The study protocol was designed in accordance with the guidelines outlined in the Declaration of Helsinki and was approved by the Ethics Committee of Sun Yat-sen University Cancer Center.

A standardized data collection form was designed to retrieve all relevant sociodemographic data (age, gender, pathologic subtype); preoperative baseline laboratory data: carcino-embryonic antigen (CEA), Carbohydrate antigen (CA199), albumin (ALB), C-reactive protein (CRP), etc.; staging data. All patients had received standard chemotherapies of FOLFIRI19 (47.2%), FOLFOX20 (33.5%), or XELOX21 (19.3%), and/or in combination with bevacizumab every 3 weeks.

Colon cancers were identified by ICD-O-3 site codes. If the cancer located in cecum, ascending colon, hepatic flexure of colon, and transverse colon, it would be defined as RCC, while those located in splenic flexure of colon, descending colon, sigmoid colon, and rectosigmoid were defined as LCC \[[@CR13], [@CR23]--[@CR28]\]. Clinical stage was reclassified according to the criteria of the American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC). Overall survival (OS) was defined as the time from the date of primary treatment to the date of death from any cause or until the date of the last follow-up and the deadline of the follow-up was November 2016.

Assessment of the CEA, CA199 and CRP {#Sec3}
------------------------------------

All samples were collected before any treatment and were tested within 24 h after collection. The supernatants were processed for analyzing CEA, CA199 on UniCelDxI 800 immunoassay system (Beckman Coulter, Brea, CA).Plasma CRP was measured using a high sensitivity assay (Beckman-Coulter, Woerden, The Netherlands) as described previously \[[@CR29]\].

MMR status determination {#Sec4}
------------------------

Immunohistochemistry was performed to examine the four most common mismatch repair proteins under the standard Envision two-step procedure. In brief, the slides were backed at 60°Cfor 2 h, cleared through xylene, rehydrated, then pre-treated in EDTA antigen retrieval buffer, treated with 3% hydrogen for 20 min to block endogenous peroxidase activities and then incubated with 10% normal goat serum at room temperature to block non-specific activity. Then, the slides were incubated overnight at 4°Cusing the following polyclonal antibodies, MLH1 (1:50; Beijing Zhong Shan -Golden Bridge Biological Technology, Beijing, China), PMS2 (1:50; Beijing Zhong Shan -Golden Bridge Biological Technology, Beijing, China), MSH2 (1:50; Beijing Zhong Shan -Golden Bridge Biological Technology, Beijing, China) and MSH6 (1:50; Beijing Zhong Shan -Golden Bridge Biological Technology, Beijing, China). After washing, the tissues were incubated with a secondary antibody (Envision; Dako, Glostrup, Denmark) for 1 h at room temperature. Finally, the sections were counterstained with 10% Mayer's hematoxylin, dehydrated and mounted in Crystal Mount. Non-neoplastic colonic mucosa, stromal cells, infiltrating lymphocytes or the centers of lymphoid follicles were accepted as internal positive control and the known MMR deficient colorectal carcinomas used as external negative controls. Immunostaining was scored by two experienced pathologists and without any prior knowledge of the patients' clinical data. Nuclear staining within tumor cells was defined as the normal expression, while complete absence of nuclear staining within tumor cells with concurrent internal positive controls was illustrated as negative protein expression. MLH1/PMS2/MSH2/MSH6 protein expression negative was defined as tumor with loss of MLH1/PMS2/MSH2/MSH6 protein visualized by light microscopy. Whatever one of these MLH1/PMS2/MSH2/MSH6 protein expressions is negative; it was defined as DMMR cohort. If the all the four protein is positive, the specimen then will de classified to the PMMR cohort.

Statistical analysis {#Sec5}
--------------------

Continuous variables were expressed as mean ± standard deviation, median and range, and were transformed into dichotomous variables at median value. The threshold of CEA and C19--9 were established at 5 ng/ml and 37 U/ml as commonly suggested \[[@CR30], [@CR31]\]. Comparisons were performed using univariate logistic regression for categorical/continuous variable. Variables achieving significance at the level of *P* \< 0.05 were entered into multivariate logistic regression analyses via stepwise procedures. Statistical data analyses were performed using SPSS 22.0 (SPSS, Chicago, IL, USA).

The PNI was calculated as10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm^3^). The optimal cutoff level for the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), CAR (C-reactive/Albumin Ratio)and PNI was determined using the median value \[[@CR32]\]. The modified Glasgow Prognostic Score (mGPS) was entered into the analysis as categorical variables as descried before \[[@CR33]\].

Kaplan--Meier method was used to calculate the OS survival curves, and difference was evaluated by the log-rank test. We also attempted to demonstrate the difference of PLR variation with the standard TNM classification between RCC and LCC using Nonparametric Test. all data has been deposited at Sun Yat-sen University Cancer Center for future reference (number RDDA2017000361).

Results {#Sec6}
=======

Patient characteristics and survival {#Sec7}
------------------------------------

A total of 1846 patients were included in the analyses for the analysis, with 744 patients in the RCC cohort and 1102 patients in the LCC. MSI status was successfully determined in 1846 patients. One thousand ninety-nine patients had received the chemotherapy and 378 patients had received radiotherapy. Patients in the training cohort were 923 patients and the other 923 patients were included in the validation cohort. The median follow-up time was for OS was 37 months (range: 4--138 months) in the whole cohort. Five-year OS was 86%in the whole cohort, 85.9% in LCC cohort and 88.7% RCC cohort, with the apparent poorer survival in the LCC (*P* = 0.003, HR = 1.475, 95% CI, 1.137--1.914), which is consistent with the previous study \[[@CR34]--[@CR37]\]. The patients' characteristics plan to compare between RCC and LCC were summarized in Tables [1](#Tab1){ref-type="table"}.Table 1Clinical and laboratory characteristics of the CRC, the RCC and the LCCCharacteristicALLTraining CohortValidation cohortNumber (%)Number (%)Number (%)ALLRCCLCCRCCLCCRCCLCCAge, years  \< 59972 (52.7%)427 (43.9%)545 (56.1%)220 (44.1%)279 (55.9%)207 (43.8%)266 (56.2%)  ≥ 59874 (47.3%)317 (36.3%)557 (63.7%)162 (38.2%)262 (61.8%)155 (34.4%)295 (65.6%)Sex Male1106 (59.9%)431 (39.0%)675 (61.0%)227 (39.6%)346 (60.4%)204 (38.3%)329 (61.7%) Female740 (40.1%)313 (42.3%)427 (57.7%)155 (44.3%)195 (55.7%)158 (40.5%)232 (59.5%)CRP, mg/L  \< 3.26923 (50.0%)312 (33.8%)611 (66.2%)160 (37.1%)271 (62.9%)152 (30.9%340 (69.1%)  ≥ 3.26923 (50.0%)432 (46.8%)491 (53.2%)222 (45.1%)270 (54.9%)210 (48.7%)221 (51.3%)WBCs, ×10^9^  \< 6.4934 (50.6%)363 (38.9%)571 (61.1%)178 (39.2%)276 (60.8%)185 (38.5%295 (61.5%)  ≥ 6.4912 (49.4%)381 (41.8%)531 (58.2%)204 (43.5%)265 (56.5%)177 (40.0%)266 (60.0%)Neutrophils, ×10^9^  \< 3.9928 (50.3%)349 (37.6%)579 (62.4%)178 (40.4%)263 (48.6%)171 (35.1%)316 (64.9%)  ≥ 3.9918 (49.7%395 (43.0%)523 (57.0%)204 (42.3%)278 (57.7%)191 (43.8%)245 (56.2%)Platelets, ×10^9^  \< 252933 (50.5%)294 (31.5%)639 (68.5%)157 (33.2%)316 (66.8%)137 (29.8%)323 (70.2%)  ≥ 252913 (49.5%)450 (49.3%)463 (50.7%)225 (50.0%)225 (50.0%)225 (48.6%)238 (51.4%)ALB, g/L  \< 40.5924 (50.1%)431 (46.6%)493 (53.4%)217 (45.4%)261 (54.6%)214 (48.0%)232 (52.0%)  ≥ 40.5922 (49.9%)313 (33.9%)609 (66.1%)165 (37.1%)280 (62.9%)148 (31.0%)329 (69.0%)CEA, ng/mL  \< 51066 (57.7%)443 (41.6%)623 (58.4%)270 (40.8%)392 (59.2%)218 (37.8%)359 (62.2%)  ≥ 5780 (42.3%)301 (38.6%)479 (61.4%)112 (42.9%)149 (57.1%)144 (41.6%)202 (58.4%)CA199, U/mL  \< 271361 (73.7%)536 (39.4%)825 (60.6%)270 (40.8%)392 (59.2%)266 (38.1%)433 (61.9%)  ≥ 27485 (27.3%)208 (42.9%)277 (57.1%)112 (42.9%)149 (57.1%)96 (42.9%)128 (57.1%)T lymphocytes, ×10^9^  \< 1.6939 (50.9%)399 (42.5%)540 (57.5%)202 (42.7%)271 (57.3%)197 (42.3%)269 (57.7%)  ≥ 1.6907 (49.1%)345 (38.0%)562 (62.0%)180 (40.0%)270 (60.0%)165 (36.1%)292 (63.9%)Monocytes, ×10^9^  \< 0.4951 (51.5%)382 (40.2%)569 (59.8%)206 (41.5%)299 (58.5%)176 (39.7%)279 (61.3%)  ≥ 0.4895 (48.5%)362 (40.4%)533 (59.6%)176 (41.2%)251 (58.8%)186 (39.7%)282 (60.3%)MMR D-MMR1613 (87.4%)588 (36.5%)1025 (63.5%)93 (66.0%)48 (34.0%)63 (68.5%)29 (31.5%) P-MMR233 (12.6%)156 (67.0%)77 (33.0%)289 (37.0%)493 (63.0%)299 (36.0%)532 (64.0%)TNM category Chemotherapy  No231 (12.5%)101 (10.6%)130 (14.5%)71 (12.7%)40 (10.9%)60 (11.8%)60 (14.5%)  Yes1499 (81.2%)799 (84.1%)700 (78.1%)429 (77.0%)300 (82.0%)430 (84.3%)340 (82.3%)  Unknown116 (6.3%)50 (5.3%)66 (7.4%)57 (10.2%)26 (7.1%)20 (3.9%)13 (3.1%) Radiotherapy  No1322 (71.6%)611 (70.1%)711 (73.0%)411 (74.5%)250 (67.4%)355 (65.7%)306 (79.9%)  Yes378 (20.5%)191 (21.9%)187 (19.2%)111 (20.1%)78 (21.0%)145 (26.9%)44 (11.5%)  Unknown146 (7.9%)70 (8.0%)76 (7.8%)30 (5.4%)43 (11.6%)40 (7.4%)33 (8.6%) TNM category  1168 (9.1%)34 (20.2%)134 (79.8%)15 (20.8%)57 (79.2%)19 (19.8%)77 (80.2%)  2839 (45.4%)376 (44.8%)463 (55.2%)176 (47.8%)192 (52.2%)200 (42.5%)271 (57.5%)  3518 (28.1%)202 (39.0%)316 (61.0%)100 (39.8%)151 (60.2%)102 (38.2%)165 (61.8%)  4321 (17.4%)132 (41.1%)189 (58.9%)91 (39.2%)141 (60.8%)41 (46.1%)48 (53.9%) PLR7441102   \< 154.96923 (50.0%)295 (32.0%)628 (68.0%)160 (34.2%)308 (65.8%135 (29.7%)320 (70.3%)   ≥ 154.96923 (50.0%)449 (48.6%)474 (51.4%)222 (48.8%)233 (51.2%)227 (48.5%)241 (51.5%) NLR   \< 2.35923 (50.0%)330 (35.8%)593 (64.2%)165 (37.1%)280 (62.9%)165 (34.5%)313 (65.5%)   ≥ 2.35923 (50.0%)414 (44.9%)509 (55.1%)217 (45.4%)261 (54.6%)197 (44.3%)248 (55.7%) PNI7441102   \< 48.88921 (49.9%)363 (39.4%)558 (60.6%)182 (40.1%)272 (59.9%)181 (38.8%)286 (61.2%)   ≥ 48.88925 (50.1%381 (41.2%)544 (58.8%)200 (42.6%)269 (57.4%)181 (39.7%)275 (60.3%) CAR7441102   \< 0.08923 (50.0%)306 (33.2%)617 (66.8%)157 (36.3%)275 (63.7%)149 (30.3%)342 (69.7%)   ≥ 0.08923 (50.0%)438 (47.5%)485 (52.5%)225 (45.8%)266 (54.2%)213 (49.3%)219 (50.7%) mGPS  01243 (67.3%)441 (35.5%)802 (64.5%)223 (37.5%)371 (62.5%)218 (33.6%)431 (66.4%)  1406 (22.0%)200 (49.3%)206 (50.7%)114 (50.2%)113 (49.8%)86 (48.0%)93 (52.0%)  2197 (10.7%)103 (52.3%)94 (47.7%)45 (44.1%)57 (55.9%58 (61.1%)37 (38.9%) Survival status  Live1586 (85.9%)660 (41.6%)926 (58.4%)316 (44.4%)396 (55.6%)344 (39.4%)530 (60.6%)  Dead260 (14.1%)84 (32.3%)176 (67.7%)66 (31.3%)145 (68.7%)18 (36.7%)31 (63.3%)*Abbreviations*: *CRP* C-reactive protein, *WBCs* White blood cells, *ALB* Albumin, *CA199* Carbohydrate Atigen 19--9, *CEA* Carcinoembryonic antigen, *MMR* Mismatch repair; *PLR* The platelet to lymphocyte ratio, *NLR* The neutrophil to lymphocyte ratio, *PNI* 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm3), *mGPS*, Glasgow Prognostic Score incorporates raised circulating C-reactive protein (CRP) and hypoalbuminemia; Undifferentiated, undifferentiated non-keratinizing carcinoma; Differentiated, differentiated carcinoma

Dfferent characteristics between RCC and LCC {#Sec8}
--------------------------------------------

Patients in the training cohort with left-sided colon cancer had early tumor stages, higher inflammatory index (CRP, pateletes, PLR, NLR, CAR, mGPS), higher tumor marker CEA, higher ALB and higher probability of microsatelite stability in the univariate analysis. All significant variables were entered into multivariate logistic regression; MMR status (*P* \< 0.001), PLT (*P* = 0.004), CEA (*P* \< 0.001), PLR (*P* = 0.011), TNM stage (*P* = 0.001) retained independent prognostic significance for the location of CRC. Detailed summaries of the multivariate analyses are shown in Tables [2](#Tab2){ref-type="table"}. All the charateristics were anlylzed in validation cohort, MMR status (*P* \< 0.001), age (*P* = 0.007), ALB (*P* \< 0.001), PLR (*P* = 0.022) and TNM stage (*P* = 0.011) were proven to be independent different prognostic factors (Table [3](#Tab3){ref-type="table"}). Obviously, MMR status, PLR, TNM stage were the significant difference demonstrated in both cohorts and PLR was the merely significant different inflammotory factor between the LCC and the RCC.Table 2Associations between the clinical and laboratory characteristics of the patients and location of CRC in univariate and multivariate logistic regression analysis in the training cohortCharacteristicUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueAge (\< 59 years vs. ≥ 59)1.2750.980--1.6600.071Gender (Male vs. Female)1.2120.926--1.5860.162CRP, mg/L (≥ 3.26 vs. \< 3.26)1.3931.069--1.8130.0140.835WBCs, ×10^9^ (≥ 6.4 vs. \< 6.4)1.1940.918--1.5520.186Neutrophils, ×10^9^ (≥ 3.9 vs. \< 3.9)1.0840.834--1.4100.546Platelets, ×10^9^ (≥ 252 vs. \< 252)2.0131.543--2.626\<0.0011.5631.151--2.1240.004ALB, g/L (≥ 40.5 vs. \< 40.5)0.7090.545--0.9220.0100.275CA199, U/mL (≥ 27 vs. \< 27)1.0910.817--1.4580.5550.635CEA, ng/mL (≥ 5 vs. \< 5)1.5041.154--1.9590.0031.8191.350--2.450\<0.001T lymphocytes, ×10^9^ (≥1.6vs. \< 1.6)0.8940.688--1.1630.404Monocytes, ×10^9^ (≥ 0.4 vs. \< 0.4)0.9870.759--1.2840.923MMR, (P vs. D)0.3030.207--0.441\<0.0010.3090.209--0.457\<0.001Chemotherapy No1.2200.911--1.6340.182 Yes1.2520.932--1.6810.135 0.237 Unknown1.0260.767--1.3720.862Radiotherapy No1.2340.920--1.6550.160 Yes1.2350.871--1.7500.237 Unknown0.9750.678--1.4010.889TNM\<0.0010.001 11.0001.0001.0001.000 23.4831.903--6.375\<0.0013.1261.665--5.869\<0.001 32.5171.351--4.6890.0042.4701.291--4.7250.006 42.4521.310--4.5900.0052.3451.217--4.5160.011PLR1.8341.407--2.391\<0.0011.4541.071--1.9751.4540.022dNLR1.4111.084--1.8360.0100.443CAR1.4821.137--1.9300.0040.428PNI1.1110.855--1.4440.431mGPS0.0040.428 01.0001.000 11.6781.233--2.2850.0010.195 21.3130.859--2.0080.2080.850*Abbreviations*: *CRP* C-reactive protein, *WBCs* White blood cells, *ALB* Albumin, *CA199* Carbohydrate Atigen 19--9, *CEA* Carcinoembryonic antigen, *MMR* Mismatch repair, *PLR* The platelet to lymphocyte ratio, *NLR* The neutrophil to lymphocyte ratio; PNI, 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm3), *mGPS* Glasgow Prognostic Score incorporates raised circulating C-reactive protein (CRP) and hypoalbuminemia; Undifferentiated, undifferentiated non-keratinizing carcinoma; Differentiated, differentiated carcinoma Table 3Associations between the clinical and laboratory characteristics of the patients and location of CRC in univariate and multivariate logistic regression analysis in the validation cohortCharacteristicUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueAge (\< 59 years vs. ≥ 59)1.4811.135--1.9330.0041.3841.036--1.8480.028Gender (Male vs. Female)1.0980.841--1.4350.491CRP, mg/L (≥ 3.26 vs. \< 3.26)2.1261.625--2.781\<0.001WBCs, ×10^9^ (≥ 6.4 vs. \< 6.4)1.0610.815--1.3820.660Neutrophils, ×10^9^ (≥ 3.9 vs. \< 3.9)1.4411.105--1.8780.007Platelets, ×10^9^ (≥ 252 vs. \< 252)1.5451.125--2.1210.007ALB, g/L (≥ 40.5 vs. \< 40.5)0.4880.373--0.638\<0.0010.5320.398--0.710\<0.001CA199, U/mL (≥ 27 vs. \< 27)1.2210.899--1.6570.200CEA, ng/mL (≥ 5 vs. \< 5)1.1740.894--1.5410.248T lymphocytes, ×10^9^ (≥1.6vs. \< 1.6)0.7720.592--1.0060.055Monocytes, ×10^9^ (≥ 0.4 vs. \< 0.4)1.0460.803--1.3620.741MMR, (P vs. D)0.2590.163--0.411\<0.0010.3170.195--0.515\<0.001TNM\<0.0010.011 11.0001.0001.0001.000 22.9911.753--5.103\<0.0012.3651.357--4.1230.002 32.5051.432--4.3840.0012.1751.215--3.8920.009 43.4621.803--6.648\<0.0012.9631.501--5.8500.002PLR2.2331.703--2.927\<0.0011.4511.056--1.9930.022NLR1.5071.155--1.9650.002CAR2.2321.705--2.923\<0.001PNI1.0400.798--1.3550.771mGPS\<0.001 01.0001.000 13.0991.989--4.828\<0.001 21.6951.022--2.8120.041*Abbreviations*: *CRP* C-reactive protein, *WBCs* White blood cells, *ALB* Albumin, *CA199* Carbohydrate Atigen 19--9, *CEA* Carcinoembryonic antigen, *MMR* Mismatch repair, *PLR* The platelet to lymphocyte ratio, *NLR* The neutrophil to lymphocyte ratio; PNI, 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm3), *mGPS* Glasgow Prognostic Score incorporates raised circulating C-reactive protein (CRP) and hypoalbuminemia; Undifferentiated, undifferentiated non-keratinizing carcinoma; Differentiated, differentiated carcinoma

PLR and survival {#Sec9}
----------------

PLR had the ability to distinguish patients had poorer survival in the LCC cohort by log-rank test (*P* = 0.002, HR = 0.1.261, 95%CI, 1.087--1.462) (Fig. [1a](#Fig1){ref-type="fig"}). However, the better survival of the lower PLR was not observed in the RCC cohort (*P* = 0.424, HR = 1.094, 95% CI, 0.877--1.365, Fig. [1b](#Fig1){ref-type="fig"}). The PLR prognostic value merely exists in the early-staged TNM staging but not the advanced stage (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A and B). Additionally, the higher PLR have poorer survival than the lower PLR in the LCC cohort (*P* = 0.002) but not the RCC (*P* = 0.869) in the early-staged TNM staging (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 C and D).Fig. 1Prognostic value of the PLR (platelet and neutrophils) for OS. **a** The whole cohort, **b** the RCC cohort, and (**c**) the LCC cohort

PLR variation with TNM staging {#Sec10}
------------------------------

The variation trend between systemic inflammatory factors and the tumor staging was shown in Fig. [2](#Fig2){ref-type="fig"}. We found that there were significant interactions between tumor stages (I to IV) with PLR in LCC cohort (*P* \< 0.001, Fig. [2a](#Fig2){ref-type="fig"}), with the lowest values in stage I and the highest in stage IV. However, the relationship did not sustain in subgroup RCC patients, as shown in (*P* = 0.174, Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2Variation of the continuous variable PLR (platelet and neutrophils) with TNM stage. **a** The whole cohort, **b** the RCC cohort, and (**c**) the LCC cohort

Discussion {#Sec11}
==========

Currently, most studies had focused on the biology, microenvironment and survival difference in RCC and LCC, however, there is still no report regarding the inflammatory distinction between them \[[@CR37]--[@CR41]\].To our knowledge this is the first population-based research exploring the inflammatory-related index disparity of tumor location in CRC.

As shown in Table [1](#Tab1){ref-type="table"}, the clinical characteristics such as TNM staging, MMR status, were significantly differ between RCC and LCC in training cohort and age, TNM staging, MMR status were different in the validation cohort. Additionally, our results showed that CRP, PLT, ALB, PLR NLR, CAR, mGPS were the different inflammatory factor between the LCC and the RCC in the training cohort. Similarly, CRP, PLT, neutrophils, ALB, PLR, NLR, CAR, mGPS were the different inflammatory index between the LCC and the RCC in the validation cohort. However, PLR was the only inflammatory index among CEA CRP, neutrophils, platelets, ALB, PLR, NLR, CAR, and mGPS that differed significantly between RCC and LCC in multivariate analysis verified in both cohorts. The other independent factors in the training cohort were PLT, CEA, MMR status, and TNM stage and age, ALB, MMR and TNM stage were the independent factor in the validation cohort. Together, our results showed that PLR might be a vital different inflammatory factor between RCC and LCC. Among these five inflammatory factors, PLR, NLR, mGPS, CAR, PNI, why is only the PLR indicating the difference between the LCC and RCC, the reasons still unknown. As the previous studies shown, that the OS or DFS (disease-free survival) prognostic value were indeed validated for these five factors in CRC \[[@CR42]--[@CR46]\]. However, there is no report regarding the difference of their prognostic value for in the LCC and RCC. We assume that other systemic inflammatory response parameters (such as NLR, PNI, mGPS, CRP, CAR) can not represent the LCC and RCC inflammatory difference is that hypoalbuminemia reflects a malnutrition but not inflammatory reaction \[[@CR47]\] and that is why the CAR, mGPS and PNI were not the representative index between the LCC and the RCC. Although the clinical significance of NLR is still unclear, it has been pointed out that this parameter may transferred between the pro-inflammatory response (i.e. high value of neutrophils and low value of lymphocytes) and an immune pattern (i.e. low value of neutrophils and high value of lymphocytes) \[[@CR42]\].

The PLR has been demonstrated as a prognostic factor in several malignant tumors, including colorectal cancer, gastric cancer, esophageal carcinoma, esophageal squamous cell carcinoma (ESCC), small cell lung cancer \[[@CR48]--[@CR52]\]. The role of both platelets and lymphocyte as independent regulators of various processes in cancer has been known for long. However, the exact mechanism of the inflammatory index difference in the LCC and RCC has not been illustrated although *Gervaz* et al. reported that CRC is a heterogeneous disease and could be differentiated into two anatomical and functional entities \[[@CR53]\].

Interestingly, the difference of PLR in our study has significantly translated into OS difference only in LCC rather than RCC, and PLR changes with TNM stage only in LCC. So, what is the inner link between PLR and LCC? According to *Guinney's* (14) research, LCC related to CMS2, which characterized as epithelial, chromosomally unstable, marked WNT and MYC signaling activation; RCC related to CMS1, which characterized as hypermutated, microsatellite unstable, strong immune activation. Obviously, LCC related to inflammation, but RCC not, so, it is consistent with the opinion that the PLR reflect inflammation too. *Chapman* et al. has demonstrated that platelets present antigen to T cells in a platelet MHCI (major histocompatibility complex I) dependent manner, which indicate platelets not only support and promote acquired immune responses, but may also directly participate in the initiation of acquired immune responses. *Liang* et al. has revealed that the over-activation of platelets enhances survival of tumor cells in circulation by the CD62P ligand \[[@CR54]\]. It has also been convincingly demonstrated that platelet addition to tumor cells can impede natural killer cell mediated recognition and elimination of tumor cells, which may prime the tumor cells for metastasis \[[@CR55]\]. Platelet could activate the epidermal growth factor receptor (EGFR) and downstream signals of DNA-dependent protein kinase (DNA-PK)-a ubiquitous DNA repair enzyme. Prior studies have shown that the formation of the EGFR: DNA-PK complex could maintain DNA repair \[[@CR56], [@CR57]\]. Therefore, we suppose that the activated platelets not only promote CTCs to survive, but also enhance metastasis ability of tumor cells directly, especially in the LCC \[[@CR58], [@CR59]\]. Platelets' role as inducers of intravascular NETosis (neutrophil extracellular traps) has also been revealed with the effect to promote thrombosis, systemic inflammation, and relapse of the tumor disease \[[@CR60]--[@CR62]\]. Beyond the routine role as chief effector cells in hemostasis and thrombosis, platelets also play a vital role as inflammatory cells since its activation is crucial for the metastasis CTCs cells to escape from immune cells attack for adapting the blood microenvironment. In sum, the activated platelets may were used as stimulator in the tumor progression and may accelerate early cancer development \[[@CR63], [@CR64]\].

Finally, with the increase of TNM stage, PLR significantly increased either in LCC rather than RCC in our study. The LCC exhibit the characteristics of higher rates of microsatellite stability (MSS) \[[@CR65]\] and a notable feature of PMMR. Concerning the clinical relevance, an inability to respond to adverse environmental stressors might have clear implications for the success of chemotherapy in these tumors. It has recently been shown that MSS tumors show a good response to chemotherapy, but those patients population with increase of PLR which represent the inflammation reaction, so, targeted inflammation or platelet may be the direction of treatment for those patients.

The study was conducted retrospectively and selection bias may exist. However, we included a relatively large cohort to assess the difference of PLR in LCC and RCC in independent training cohort and validation cohort. Of course, additional validation of the PLR is necessary in prospective datasets. In summary, this study suggests that the prognostic value of the PLR, a continuous variable, may help to stratify LCC and RCC patient and guide treatment especially in the LCC.

Conclusion {#Sec12}
==========

This is the first study that regarding the inflammatory status between the LCC and the RCC and we found the PLR was the merely different inflammatory parameter between the LCC and the RCC. Additionally, the PLR variation trend with the tumor staging was shown in only in the LCC.

Additional file {#Sec13}
===============

Additional file 1: Figure S1.The prognostic value in the stratified TNM staging (A, staging I + II + III; B, staging IV); The prognostic value in the LCC (C) and the RCC (D) in the staging I + II + III, respectively. (TIFF 13481 kb)

ALB

:   Albumin

CA199

:   Carbohydrate antigen

CEA

:   Carcino-embryonic antigen

CMS

:   Consensus molecular subtypes

CRC

:   Colon cancer

CRP

:   C-reactive protein

d-MMR

:   Mismatch repair deficiency

DNA-PK

:   DNA-dependent protein kinase

ESCC

:   Esophageal squamous cell carcinoma

LCC

:   Left-sided colon cancer

mGPS

:   Glasgow prognostic score

MHCI

:   Major histocompatibility complex I

MSI-high

:   Microsatellite instability-high

MSS

:   Microsatellite stability

NETosis

:   Neutrophil extracellular traps

NK

:   Natural killer cell

NLR

:   Neutrophil lymphocyte ratio

OS

:   Overall survival

PFS

:   Progression-free survival

PLR

:   Platelet lymphocyte ratio

P-MMR

:   Mismatch repair--proficient

p-MMR

:   Mismatch-repair proficient

PNI

:   Nutritional Index

RCC

:   Right-sided colon cancer
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